Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition.
作者： J. Cory Kalvass , Gary M. Pollack
DOI: 10.1007/S11095-006-9135-X
关键词:
摘要: Purpose Unexpected and complex experimental observations related to efflux transport have been reported in the literature. This work was conducted develop relationships for activity (PSefflux) as a function of commonly studied kinetic parameters [permeability-surface area product (PS), ratio (ER), degree inhibition (ϕi), 50% inhibitory concentration (IC50), Michaelis–Menten constant (Km)].
springer.com
sci-hub.se 参考文章(31)
Hilary Thomas, Helen M. Coley, Overcoming Multidrug resistance in cancer: An update on the clinical strategy of inhibiting P-glycoprotein Cancer Control. ,vol. 10, pp. 159- 165 ,(2003) , 10.1177/107327480301000207
Claude Dagenais, Jian Zong, Julie Ducharme, Gary M. Pollack, Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharmaceutical Research. ,vol. 18, pp. 957- 963 ,(2001) , 10.1023/A:1010984110732
Matthew D. Troutman, Dhiren R. Thakker, Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharmaceutical Research. ,vol. 20, pp. 1192- 1199 ,(2003) , 10.1023/A:1025096930604
Yasuhisa Adachi, Hiroshi Suzuki, Yuichi Sugiyama, Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharmaceutical Research. ,vol. 18, pp. 1660- 1668 ,(2001) , 10.1023/A:1013358126640
A Sadeque, Increased drug delivery to the brain by P-glycoprotein inhibition. Clinical Pharmacology & Therapeutics. ,vol. 68, pp. 231- 237 ,(2000) , 10.1067/MCP.2000.109156
R HO, R KIM, Transporters and drug therapy: implications for drug disposition and disease. Clinical Pharmacology & Therapeutics. ,vol. 78, pp. 260- 277 ,(2005) , 10.1016/J.CLPT.2005.05.011
J. Cory Kalvass, Candace L. Graff, Gary M. Pollack, Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice. Pharmaceutical Research. ,vol. 21, pp. 1867- 1870 ,(2004) , 10.1023/B:PHAM.0000045241.26925.8B
Hiroyuki Kusuhara, Yuichi Sugiyama, Efflux transport systems for drugs at the blood–brain barrier and blood–cerebrospinal fluid barrier (Part 1) Drug Discovery Today. ,vol. 6, pp. 150- 156 ,(2001) , 10.1016/S1359-6446(00)01632-9
Todd Hulgan, John P. Donahue, Charlene Hawkins, Derya Unutmaz, Richard T. D'Aquila, Stephen Raffanti, Fred Nicotera, Peter Rebeiro, Husamettin Erdem, Melissa Rueff, David W. Haas, Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy Journal of Acquired Immune Deficiency Syndromes. ,vol. 34, pp. 119- 126 ,(2003) , 10.1097/00126334-200310010-00001
Claude Dagenais, Candace L. Graff, Gary M. Pollack, Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochemical Pharmacology. ,vol. 67, pp. 269- 276 ,(2004) , 10.1016/J.BCP.2003.08.027